Third-generation inhibitors targeting EGFR T790M mutation in advanced non-small cell lung cancer - Wikidata - wikimedia - TriplyDB

Third-generation inhibitors targeting EGFR T790M mutation in advanced non-small cell lung cancer

Third-generation inhibitors targeting EGFR T790M mutation in advanced non-small cell lung cancer

http://www.wikidata.org/entity/Q26748851

about

EGFR C797S mutation mediates resistance to third-generation inhibitors in T790M-positive non-small cell lung cancer The role of HGF/c-MET signaling pathway in lymphoma Tyrosine kinase inhibitors and mesenchymal stromal cells: effects on self-renewal, commitment and functions Inhibition of the fibroblast growth factor receptor (FGFR) pathway: the current landscape and barriers to clinical application Next-generation EGFR/HER tyrosine kinase inhibitors for the treatment of patients with non-small-cell lung cancer harboring EGFR mutations: a review of the evidence Exploratory cohort study and meta-analysis of BIM deletion polymorphism in patients with epidermal growth factor receptor-mutant non-small-cell lung cancer treated with epidermal growth factor receptor tyrosine kinase inhibitors Discovery and characterization of a novel irreversible EGFR mutants selective and potent kinase inhibitor CHMFL-EGFR-26 with a distinct binding mode.Efficacy of continuous EGFR-inhibition and role of Hedgehog in EGFR acquired resistance in human lung cancer cells with activating mutation of EGFR Meta-analysis of the impact of de novo and acquired EGFR T790M mutations on the prognosis of patients with non-small cell lung cancer receiving EGFR-TKIs.New developments in the treatment of advanced squamous cell lung cancer: focus on afatinib.Comparison of the effectiveness of erlotinib, gefitinib, and afatinib for treatment of non-small cell lung cancer in patients with common and rare EGFR gene mutations.MicroRNA-330-3p promotes cell invasion and metastasis in non-small cell lung cancer through GRIA3 by activating MAPK/ERK signaling pathway.Serial cfDNA assessment of response and resistance to EGFR-TKI for patients with EGFR-L858R mutant lung cancer from a prospective clinical trial Apatinib as post second-line therapy in EGFR wild-type and ALK-negative advanced lung adenocarcinoma.Mutational profiling of non-small-cell lung cancer patients resistant to first-generation EGFR tyrosine kinase inhibitors using next generation sequencing.Epidermal growth factor receptor T790M mutation-positive metastatic non-small-cell lung cancer: focus on osimertinib (AZD9291).EGFR mutation in squamous cell carcinoma of the lung: does it carry the same connotation as in adenocarcinomas?Osimertinib in the treatment of non-small-cell lung cancer: design, development and place in therapy Lysine-Targeting Covalent Inhibitors.Beyond disease-progression: Clinical outcomes after EGFR-TKIs in a cohort of EGFR mutated NSCLC patients.ErbB Family Signalling: A Paradigm for Oncogene Addiction and Personalized Oncology.Cordycepin Induces Apoptosis and Inhibits Proliferation of Human Lung Cancer Cell Line H1975 via Inhibiting the Phosphorylation of EGFR.Osimertinib (AZD9291), a Mutant-Selective EGFR Inhibitor, Reverses ABCB1-Mediated Drug Resistance in Cancer Cells.Anti-EGFR Agents: Current Status, Forecasts and Future Directions.Mechanisms of resistance to third-generation EGFR tyrosine kinase inhibitors.Targeting the EGFR T790M mutation in non-small-cell lung cancer.Advances in the Development of Molecularly Targeted Agents in Non-Small-Cell Lung Cancer.Osimertinib: A Review in T790M-Positive Advanced Non-Small Cell Lung Cancer.BRCA2, EGFR, and NTRK mutations in mismatch repair-deficient colorectal cancers with MSH2 or MLH1 mutations.Treating EGFR mutation resistance in non-small cell lung cancer - role of osimertinib.New prognostic biomarkers and therapeutic effect of bevacizumab for patients with non-small-cell lung cancer.Clinical trials of tyrosine kinase inhibitors for lung cancer in China: a review Inhibition of Skp2 sensitizes lung cancer cells to paclitaxel.An Irreversible Inhibitor of HSP72 that Unexpectedly Targets Lysine-56 Repression of YAP by NCTD disrupts NSCLC progression.EGFR targeted therapy in lung cancer; an evolving story Survival Patterns of 5750 Stereotactic Radiosurgery-Treated Patients with Brain Metastasis as a Function of the Number of Lesions.The emerging roles of NGS-based liquid biopsy in non-small cell lung cancer.Comparative Network Analysis of Patients with Non-Small Cell Lung Cancer and Smokers for Representing Potential Therapeutic Targets.Monitoring Daily Dynamics of Early Tumor Response to Targeted Therapy by Detecting Circulating Tumor DNA in Urine.

P2860

Q26741998-FC1EDEA7-39A1-46F7-96F5-17E59C57D078 Q28069836-763C39A2-37FE-4C3C-B00F-1D4E40CCB4BE Q28078946-5449D339-FE7E-4C83-BAFB-D0EB552E7384 Q28079309-9F3117B8-4563-418C-9851-751BAB568DCF Q28079320-AC6CCDF3-7ED3-48A9-A5ED-E3E4515222BC Q33553528-1B30331A-EFCA-434C-869B-62BE4127CD26 Q33566948-DC261363-876D-4412-AD15-CA194D34CBA8 Q33618558-E79A26AE-C31E-4924-9990-3935CEE13918 Q33621143-42A7D80C-F4AB-4562-AFC2-C6C5EFE73A92 Q33704088-EE31A269-C72E-49C6-97B6-BAE55FF22C20 Q33751194-AF18EE5A-6333-4113-918E-C6B6FF8E623D Q33814564-67390474-3F63-4A54-A72E-573842DB5D94 Q37251422-D8F0C81C-B09D-4016-A822-AAF7619D7392 Q37603669-A3E13BEC-5A99-49C3-A0FF-D9B490E9B718 Q37641681-FE4E8C3C-E8D8-49B2-AC15-DD15F7941D47 Q37726138-2F4D5684-27B4-4896-AE0C-55CF398E68A2 Q37735770-D71D3A5C-B589-4657-978F-909B04DEFC26 Q38598893-EBF0389E-6108-47E8-84E5-9EB5A1CE53A4 Q38635726-7DF991C2-9B29-48A3-B062-607609A1310F Q38640618-E81DB9D1-C497-4E1E-BD27-725612AF9A09 Q38729111-B60BFE27-6887-498E-8660-352136989A5F Q38743023-8BAC5A23-0BE3-43D0-8293-A20F735BBBDA Q38744729-3D349D25-10EE-4B27-AB16-0EBF43C54079 Q38832105-6FABCD6A-BEA4-453E-B6B6-D56CEE2A2872 Q38988061-9E32ECE1-5955-42E9-A79B-1D7B9CBB57E6 Q39047294-DC7CF1EA-3659-4F3C-9541-55EAF37EDAA7 Q39220897-DE34A477-3063-4DD5-A7E1-218E1A9E14A4 Q39436392-3809D804-40FE-491B-9C5C-8CFEFCAD49A1 Q41093124-26DB188C-0806-4863-A654-ED5290F49AB5 Q41189462-C7BBC7E3-4AEC-4CCB-A687-7D8B6007AB68 Q41283854-0888A828-3E0E-4C44-965F-04F59986F9FE Q41292062-564802E2-9553-4C73-B16B-181D3E9C073E Q42236386-F4CFA9AC-393A-492E-B76E-512A0DEB4414 Q42289932-55D5755B-2F1D-43F9-B1DE-F1EAA2F5C23F Q42315519-7FAEA345-8233-4381-977F-9CFF94D02A6F Q42322394-7881C67D-C09A-4DE4-BEA2-C91E0650737D Q42640457-B4374525-6B27-42DB-BA6A-F92167B2B9E1 Q42643276-53E82F86-9F96-49CB-89DA-46CEA7E2C99F Q44646012-0BB7615E-426F-46B1-AA1F-F6393AEAA988 Q46633214-E0FD607D-27A5-45E8-835B-473903F054E4

P2860

Third-generation inhibitors targeting EGFR T790M mutation in advanced non-small cell lung cancer

http://www.wikidata.org/entity/Q26748851

description

2016 nî lūn-bûn

@nan

2016 թուականի Ապրիլին հրատարակուած գիտական յօդուած

@hyw

2016 թվականի ապրիլին հրատարակված գիտական հոդված

@hy

2016年の論文

@ja

2016年論文

@yue

2016年論文

@zh-hant

2016年論文

@zh-hk

2016年論文

@zh-mo

2016年論文

@zh-tw

2016年论文

@wuu

name

Third-generation inhibitors ta ...... ced non-small cell lung cancer

@ast

Third-generation inhibitors ta ...... ced non-small cell lung cancer

@en

Third-generation inhibitors ta ...... ced non-small cell lung cancer

@nl

type

label

Third-generation inhibitors ta ...... ced non-small cell lung cancer

@ast

Third-generation inhibitors ta ...... ced non-small cell lung cancer

@en

Third-generation inhibitors ta ...... ced non-small cell lung cancer

@nl

prefLabel

Third-generation inhibitors ta ...... ced non-small cell lung cancer

@ast

Third-generation inhibitors ta ...... ced non-small cell lung cancer

@en

Third-generation inhibitors ta ...... ced non-small cell lung cancer

@nl

P1433

Q26748851-0002084B-3240-4B83-A2DA-132E33420DD8

P1476

Q26748851-3B41D439-EEFD-4E92-BCCF-828CAAB6C862

P2093

Q26748851-4897BDCA-AFBA-47E6-991D-81FB7C40F77D

Q26748851-4D1D10EF-3DE4-4A81-AAAC-7D5C02140DD3

Q26748851-AAD93F49-5B5E-402E-97FF-897168667964

P275

Q26748851-24528BBD-75EA-48E7-98F1-C786C956CBBC

P2860

Q26748851-0578EC5A-1DEC-4D43-9502-4354B38F98C8

Q26748851-0BF16420-4C98-44BE-9ACE-202D9C345A89

Q26748851-11B78FCB-D2DE-4ADC-BB45-A04694D2F47D

Q26748851-12FF21DF-5C19-421F-8C2A-371F0159FCC7

Q26748851-1707898D-2834-478D-B2AE-15A91BD53384

Q26748851-18B39812-F25E-40D5-9F77-5568FF058387

Q26748851-3783E924-3EEC-40E2-8CEB-D022444BA67C

Q26748851-3A3A5384-F174-4716-BBD1-3A5B903D8934

Q26748851-3B52A341-6A4D-4B3D-8C61-5467DEDBCBD1

Q26748851-3EDB8187-B47E-4B3C-AE14-5EDFFC20835B

P2888

Q26748851-2D04498B-A2B6-47CF-BEDC-FAE31B8B4E69

P304

Q26748851-5EC9A3C2-77FC-4D92-A96A-BD4267187CEF

P31

Q26748851-9CCF8100-E248-411F-BA74-8C35321051C1

Q26748851-BECF4356-87B9-4702-822C-637013602098

P3181

Q26748851-C7A8172B-DB92-4316-A8DA-4247A13B1351

P356

Q26748851-543818A6-B69E-43C4-887E-0B06B6340CAD

P407

Q26748851-0CA8025D-BF67-4186-ADA6-C7DF0E222810

P433

Q26748851-B1451023-8EB3-4327-9E0B-2D818F863CA9

P478

Q26748851-69F3206B-A0CC-4DF3-AEAC-532E5135DBC2

P5008

Q26748851-9EE747FD-59A1-4084-8107-F7FA0E8E271D

P577

Q26748851-6B48750F-ACDF-447C-9037-432356802339

P6179

Q26748851-67CFAAAC-1651-40A5-9AE5-C3ED4B4748F7

P698

Q26748851-2EE2ACBB-39EE-4923-B85D-6894037C03EA

P921

Q26748851-1AE83943-BE6E-4F7F-AB9D-27E9E5811B80

Q26748851-3F15B8F7-5FA8-4701-A69F-8F0BC8B9D0BB

Q26748851-90286892-8EEF-4619-A75A-E0053404EBB5

Q26748851-A8885202-F08B-4A7F-9F38-789700ABCC4E

Q26748851-AB86E6EB-C015-497A-B88C-4BA38ABE3D50

Q26748851-C22571C5-02FC-4621-8F03-F4F643C5CA92

Q26748851-CCED87B4-3617-4F16-904D-DBD120BFCA9A

Q26748851-E2A08535-E734-4285-8ECA-C8CBD3F5224B

P932

Q26748851-D69CB11A-7CC8-4D01-9898-CE602387DC04

P3181

P356

S13045-016-0268-Z

P1433

Journal of Hematology & Oncology

P1476

Third-generation inhibitors ta ...... ced non-small cell lung cancer

@en

P2093

Delong Liu

http://www.w3.org/2001/XMLSchema#string

Shuhang Wang

http://www.w3.org/2001/XMLSchema#string

Shundong Cang

http://www.w3.org/2001/XMLSchema#string

P275

Creative Commons Attribution 4.0 International

P2860

Non-invasive approaches to monitor EGFR-TKI treatment in non-small-cell lung cancer

Structure- and reactivity-based development of covalent inhibitors of the activating and gatekeeper mutant forms of the epidermal growth factor receptor (EGFR)

Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors

Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial.

Analysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers.

Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations.

Discovery of a mutant-selective covalent inhibitor of EGFR that overcomes T790M-mediated resistance in NSCLC.

Ceritinib in ALK-rearranged non-small-cell lung cancer.

AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer

AZD9291 in EGFR inhibitor-resistant non-small-cell lung cancer.

P2888

s13045-016-0268-z

P304

34

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

8357

http://www.w3.org/2001/XMLSchema#string

P356

10.1186/S13045-016-0268-Z

http://www.w3.org/2001/XMLSchema#string

P407

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

9

http://www.w3.org/2001/XMLSchema#string

P5008

P577

2016-04-12T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1032766738

http://www.w3.org/2001/XMLSchema#string

P698

27071706

http://www.w3.org/2001/XMLSchema#string

P921

cell surface receptor

mechanism of action

genetic variation

non-small-cell lung carcinoma

membrane proteins

P932

4830020

http://www.w3.org/2001/XMLSchema#string